Menu
/REGISTER
Montecito
Nixon Peabody
Chase
Bank of America
Loading...
You are here:  Home  >  Central Coast Health Watch  >  Current Article

Amgen gets FDA OK to market Repatha’s ability to prevent heart attacks

By   /   Friday, December 1st, 2017  /   Comments Off on Amgen gets FDA OK to market Repatha’s ability to prevent heart attacks

    Print       Email
The U.S Food and Drug Administration gave Thousand Oaks biotech giant Amgen the go-ahead to market its cholesterol drug Repatha to patients at risk of a heart attack or stroke. Shares for the company rose around 1 percent after the news, ending at $177.51 in after-hours trading. The drug brought in around $58 million for…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Mindbody’s Stollmeyer to be executive chair of the board

Read More →